World’s first EpiCor yeast fermentate lozenge launched in New Zealand
The product, Viralex Soothe EpiCor, become available across New Zealand this march through Good Health Products.
EpiCor is widely available across the world and is clinically shown to support a strong immune system.
Julia van de Coolwijk, Good Health’s marketing manager said the company had already been been using EpiCor in its Viralex Attack capsules, for which it had seen sales grow by almost 75%.
“We wanted to leverage the success of EpiCor by providing this unique ingredient in a different format and to specifically target a different cold and flu symptom: sore throats. We have also developed this product to be complementary to our existing Viralex range.”
“EpiCor provides a differentiated product by being natural and fast acting. It was also an effective material for making into a high-boil lozenge and with exclusivity in the New Zealand market it provides us with an ingredient that enables a strong and unique point of difference from our competitors.”
Jeff Cannon, chief executive of Embria’s parent, Diamond V, said: “Embria strives for partnerships with our brand customers. In a short period of time Good Health has become a valued partner of Embria’s in the New Zealand marketplace and a very effective marketer of seasonal products featuring EpiCor.”
